JPWO2023107697A5 - - Google Patents
Info
- Publication number
- JPWO2023107697A5 JPWO2023107697A5 JP2024533948A JP2024533948A JPWO2023107697A5 JP WO2023107697 A5 JPWO2023107697 A5 JP WO2023107697A5 JP 2024533948 A JP2024533948 A JP 2024533948A JP 2024533948 A JP2024533948 A JP 2024533948A JP WO2023107697 A5 JPWO2023107697 A5 JP WO2023107697A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- dose
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288377P | 2021-12-10 | 2021-12-10 | |
| US63/288,377 | 2021-12-10 | ||
| US202263421524P | 2022-11-01 | 2022-11-01 | |
| US63/421,524 | 2022-11-01 | ||
| US202263429376P | 2022-12-01 | 2022-12-01 | |
| US63/429,376 | 2022-12-01 | ||
| PCT/US2022/052411 WO2023107697A1 (en) | 2021-12-10 | 2022-12-09 | Methods of administering a modulator of hemoglobin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024545496A JP2024545496A (ja) | 2024-12-09 |
| JP2024545496A5 JP2024545496A5 (https=) | 2025-10-06 |
| JPWO2023107697A5 true JPWO2023107697A5 (https=) | 2025-10-06 |
Family
ID=85108880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533948A Pending JP2024545496A (ja) | 2021-12-10 | 2022-12-09 | ヘモグロビンのモジュレーターを投与する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041312A1 (https=) |
| EP (1) | EP4444285A1 (https=) |
| JP (1) | JP2024545496A (https=) |
| KR (1) | KR20240116826A (https=) |
| AU (1) | AU2022408097B2 (https=) |
| CA (1) | CA3241881A1 (https=) |
| IL (1) | IL312835A (https=) |
| MX (1) | MX2024007064A (https=) |
| TW (1) | TW202339732A (https=) |
| WO (1) | WO2023107697A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4727555A1 (en) * | 2023-06-13 | 2026-04-22 | Global Blood Therapeutics, Inc. | (s)-2-hydroxy-6-((4-(2-(2-hydroxyethyl)nicotinoyl)morpholin-3-yl)methoxy)benzaldehyd for use in the treatment of sickle cell disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| PT3880654T (pt) * | 2018-11-19 | 2022-04-08 | Global Blood Therapeutics Inc | Compostos de 2-formil-3-hidroxifeniloximetil capazes de modular hemoglobina |
| EP4337659A1 (en) * | 2021-05-14 | 2024-03-20 | Global Blood Therapeutics, Inc. | Solid forms of a modulator of hemoglobin |
-
2022
- 2022-12-09 EP EP22847662.8A patent/EP4444285A1/en active Pending
- 2022-12-09 KR KR1020247023029A patent/KR20240116826A/ko active Pending
- 2022-12-09 CA CA3241881A patent/CA3241881A1/en active Pending
- 2022-12-09 JP JP2024533948A patent/JP2024545496A/ja active Pending
- 2022-12-09 MX MX2024007064A patent/MX2024007064A/es unknown
- 2022-12-09 US US18/717,181 patent/US20250041312A1/en active Pending
- 2022-12-09 WO PCT/US2022/052411 patent/WO2023107697A1/en not_active Ceased
- 2022-12-09 TW TW111147489A patent/TW202339732A/zh unknown
- 2022-12-09 AU AU2022408097A patent/AU2022408097B2/en active Active
- 2022-12-09 IL IL312835A patent/IL312835A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4125896B1 (en) | Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof | |
| EP4322942A1 (en) | Combination comprising everolimus and amcenestrant | |
| JP2003510275A (ja) | ロテプレドノールと抗ヒスタミン薬の新規な組み合わせ物 | |
| JPH10510241A (ja) | Ｉｉ型糖尿病治療薬剤としてのケトコナゾール、および、その関連物質の使用法 | |
| TW202545526A (zh) | 低劑量三重組合調配物 | |
| JPWO2007046347A1 (ja) | 筋萎縮性側索硬化症患者の運動神経保護用医薬 | |
| WO2020175817A1 (ko) | 섬유증의 예방, 개선 또는 치료용 조성물 | |
| US20050043274A1 (en) | Pharmaceutical compositions and methods for lowering blood pressure and pulse rate | |
| JP2022058873A5 (https=) | ||
| JPWO2023107697A5 (https=) | ||
| EP1935424A1 (en) | Pharmaceutical compositions comprising combined antidiabetic substances for use in diabetes mellitus | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| CN118252833A (zh) | Vofopitant用于治疗肺纤维化的用途 | |
| JPWO2023018904A5 (https=) | ||
| CN106507666A9 (zh) | 1，3‑丙二磺酸或其药学上可接受的盐用于治疗肉样瘤病的用途 | |
| JPWO2022101227A5 (https=) | ||
| CN112512526B (zh) | 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途 | |
| CN114401724B (zh) | 一种降糖药物组合物 | |
| CA2869243C (en) | Composition for the treatment of inflammatory and immune disorders | |
| JP2006519881A5 (https=) | ||
| TWI672145B (zh) | 預防及／或治療代謝疾病的醫藥組合物及其用途 | |
| CN1635893A (zh) | 用来治疗原发性头痛的复合维生素的应用 | |
| JPWO2023097276A5 (https=) | ||
| JPS6054320A (ja) | 腎疾患治療剤 | |
| CN1378451A (zh) | 用于治疗银屑病的药物组合物 |